UCART 19

Drug Profile

UCART 19

Alternative Names: CD19CAR/RQR8+_TCRαβ–_T-cells; UCART19

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator Cellectis
  • Developer Cellectis; Pfizer; Servier
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia

Most Recent Events

  • 09 Mar 2017 US FDA approves IND application for UCART 19 in Acute lymphoblastic leukaemia
  • 01 Feb 2017 Servier files an IND application with the US FDA for Acute lymphoblastic leukaemia
  • 01 Aug 2016 Phase-I clinical trials in Acute lymphoblastic leukaemia (Second-line therapy or greater) in United Kingdom (IV) (NCT02746952)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top